| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/30/2006 | US7053111 Autoimmune disease; organ transplanting; controlling cell proliferation, cell differentiation |
| 05/30/2006 | US7053107 Antiproliferative agents, angiogenesis inhibitors for treating cancer, eye disorders, diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis; N-Cyclopropyl-2-{3-[(E)-2-(4-methyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-benzamide |
| 05/30/2006 | US7053105 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| 05/30/2006 | US7053099 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors |
| 05/30/2006 | US7053098 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors |
| 05/30/2006 | US7053095 A pyridyl-2yl-4-[1,2,3-triazole] derivatives therapeutic agent for treating cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, hyperplasia, restenosis, skin disorders |
| 05/30/2006 | US7053091 Androgen sensitive diseases; prostate cancer; skin disorders; alopecia |
| 05/30/2006 | US7053090 Antiinflammatory agents; antihistamines; skin disorders; antiarthritic agents; antidiabetic agents; autoimmune disease |
| 05/30/2006 | US7053086 For cancer therapy |
| 05/30/2006 | US7053072 Methods for the administration of amifostine and related compounds |
| 05/30/2006 | US7053071 Induction of apoptosis in cancer cells |
| 05/30/2006 | US7053070 Antiproliferative agents; anticarcinogenic agents; viricides |
| 05/30/2006 | US7053065 Vitamin B12 and pemetrexed disodium combination therapies |
| 05/30/2006 | US7053058 For inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia |
| 05/30/2006 | US7053057 Caspase inhibitors and uses thereof |
| 05/30/2006 | US7053050 administering erythropoietin receptor antagonist or mimetics thereof |
| 05/30/2006 | US7052909 activation of natural killer T-lymphocytes(NKT) using phosphatidylinositol mannoside(PIM); prophylaxis of skin disorders, cancers or tuberculosis |
| 05/30/2006 | US7052906 Synthetic transmembrane components |
| 05/30/2006 | US7052903 Compositions and methods for activating genes of interest |
| 05/30/2006 | US7052896 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 05/30/2006 | US7052860 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/30/2006 | US7052832 Determining sensitivity of a cell to reovirus infection; obtain cells, monitor ras protein signaling, consistent signaling indicates sensitivity to reovirus infection |
| 05/30/2006 | US7052720 Spheroid preparation |
| 05/30/2006 | US7052703 T-cell receptorγ alternate reading frame protein, (TARP) and uses thereof |
| 05/30/2006 | US7052689 Preventing viral replication in cells; obtain cells, incubate with viricide, monitor cells for reduced viral activity |
| 05/30/2006 | US7052674 Prokineticin polypeptides, related compositions and methods |
| 05/30/2006 | CA2321380C 6-azauracil derivatives as thyroid receptor ligands |
| 05/30/2006 | CA2237594C Fused imidazole derivatives as multidrug resistance modulators |
| 05/30/2006 | CA2200220C Drug for tumor growth suppression |
| 05/30/2006 | CA2106613C Benzoylguanidines, process for their preparation, their use as a medicament and medicament containing them |
| 05/30/2006 | CA2087525C Adoptive immunotherapy with interleukin-7 |
| 05/26/2006 | WO2006055760A1 Triazole compounds that modulate hsp90 activity |
| 05/26/2006 | WO2006055697A2 Cancer immunotherapy incorporating p53 |
| 05/26/2006 | WO2006055659A2 Fixed dose combination op dutasteride and tamsulosin |
| 05/26/2006 | WO2006055638A2 Fully human monoclonal antibodies to il-13 |
| 05/26/2006 | WO2006055526A2 Compositions useful to treat ocular neovascular diseases and macular degeneration |
| 05/26/2006 | WO2006055418A1 Cyclosporine for treating mucin deficiency |
| 05/26/2006 | WO2006054908A1 Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| 05/26/2006 | WO2006054793A1 Benzofuran compound and pharmaceutical composition containing the same |
| 05/26/2006 | WO2006054773A1 Activation of caspase in the cell division stage of cancer cells and utilization of caspase inhibitor in anticancer agent and so on |
| 05/26/2006 | WO2006054757A1 Caspase inhibitor |
| 05/26/2006 | WO2006054710A1 Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer |
| 05/26/2006 | WO2006054625A1 Cancer-cell-specific cytostatic agent |
| 05/26/2006 | WO2006054555A1 Medicinal composition for treating cancer or diabetes |
| 05/26/2006 | WO2006054456A1 Crystal of two-ring heterocyclic sulfonamide compound |
| 05/26/2006 | WO2006054314A1 Polymorphic forms of imatinib mesylate |
| 05/26/2006 | WO2006054177A1 Improved treatment of cancer using tlr3 agonists |
| 05/26/2006 | WO2006054143A1 Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine |
| 05/26/2006 | WO2006054129A1 Improved treatment of cancer by double-stranded rna |
| 05/26/2006 | WO2006054119A1 Topical formulations for use in the treatment or prevention of dermatological conditions |
| 05/26/2006 | WO2006054102A1 Microcin b17 analogs and methods for their preparation and use |
| 05/26/2006 | WO2006053903A2 Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors |
| 05/26/2006 | WO2006053861A1 Oligonucleotides that induce the secretion of gm-csf |
| 05/26/2006 | WO2006053755A1 Pharmaceutical compositions comprising a camtothecin derivate |
| 05/26/2006 | WO2006053707A1 Novel derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, and uses thereof in photodynamic therapy |
| 05/26/2006 | WO2006053445A1 Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer |
| 05/26/2006 | WO2006053390A1 A method of modulating b cell functioning |
| 05/26/2006 | WO2006053379A1 Improved nutraceutical composition |
| 05/26/2006 | WO2006031786A3 Protein a compositions and methods of use |
| 05/26/2006 | WO2006024486A3 Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| 05/26/2006 | WO2006006079A3 Methods for suppressing neovascularization using ephrinb2 |
| 05/26/2006 | WO2006003123A3 Radionuclides for medical use |
| 05/26/2006 | WO2005110438A3 Methods and products related to the intracellular delivery of polysaccharides |
| 05/26/2006 | WO2005099769A3 Novel g-csf conjugates |
| 05/26/2006 | WO2005084754A3 Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation |
| 05/26/2006 | WO2005058360A3 Radiation therapy and medical imaging using uv emitting nanoparticles |
| 05/26/2006 | WO2005018677A3 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| 05/26/2006 | CA2588157A1 Cancer immunotherapy incorporating p53 |
| 05/26/2006 | CA2588066A1 Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis |
| 05/26/2006 | CA2587903A1 Fully human monoclonal antibodies to il-13 |
| 05/26/2006 | CA2587727A1 Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| 05/26/2006 | CA2587676A1 Improved treatment of cancer by double-stranded rna |
| 05/26/2006 | CA2587533A1 Amide derivatives, their manufacture and use as pharmaceutical agents |
| 05/26/2006 | CA2587407A1 A method of modulating b cell functioning |
| 05/26/2006 | CA2587391A1 Compositions useful to treat ocular neovascular diseases and macular degeneration |
| 05/26/2006 | CA2587224A1 Microcin b17 analogs and methods for their preparation and use |
| 05/26/2006 | CA2586612A1 Triazole compounds that modulate hsp90 activity |
| 05/26/2006 | CA2586228A1 Histone deacetylase inhibitors and methods of use |
| 05/26/2006 | CA2584343A1 Pharmaceutical compositions comprising a camptothecin derivate |
| 05/25/2006 | WO2005033098A9 Salts and polymorphs of a pyrrole-substituted indolinone compound |
| 05/25/2006 | US20060111551 Peptide having HTLV-1-specific CTL-inducing activity |
| 05/25/2006 | US20060111424 Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione |
| 05/25/2006 | US20060111418 Blood-brain barrier disruption inhibitor |
| 05/25/2006 | US20060111408 Therapeutic benzothiazole compounds |
| 05/25/2006 | US20060111401 Taxanes having a C10 carbonate substituent |
| 05/25/2006 | US20060111400 Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
| 05/25/2006 | US20060111397 Methods and compositions for treating diseases associated with excesses in ACE |
| 05/25/2006 | US20060111390 Azaindoles as inhibitors of c-jun n-terminal kinases |
| 05/25/2006 | US20060111389 Therapeutic acridone and acridine compounds |
| 05/25/2006 | US20060111387 Immonomoderators; viricides; anticancer agents; for example, 2-Butyl-1-isobutyl-7-(thiophen-3-yl)-1H-imidazo[4,5-c]quinolin-4-amine; use of these compounds for inducing or inhibiting cytokine biosynthesis in animals |
| 05/25/2006 | US20060111375 Compound having tgfß inhibitory activity and medicinal composition containing the same |
| 05/25/2006 | US20060111374 N-(3-amino-propyl)-N-[1-(3-benzyl-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl)-2-methyl-propyl]-4-methyl-benzamide; kinesin spindle protein inhibitor; cell division, mitosis phase arrest; antiproliferative and antiinflammation agent, hyperplasias, restenosis, cardiac hypertrophy, autoimmune disorders |
| 05/25/2006 | US20060111371 Protein tyrosine kinase inhibitors |
| 05/25/2006 | US20060111368 Phosphodiesterase inhibitor |
| 05/25/2006 | US20060111367 Lung cancer, gastric cancer, liver cancer, leucocythemia, endometrioma, oophoroma, mammary cancer, colon cancer, prostatic cancer, or pituitary gland cancer; N (N',N'-dimethylaminoethyl)benzo[b]thieno[2,1-c]naphthalimide |
| 05/25/2006 | US20060111362 1,3-Dihydroimidazole ring compound |
| 05/25/2006 | US20060111340 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 05/25/2006 | US20060111329 Anticancer Agents Based on Regulation of Protein Prenylation |
| 05/25/2006 | US20060111328 matrix metalloproteinases (MMPs) inhibitor; N-(1-cyclohexylethyl)carbamoylphosphonic acid; anticarcinlgenic, coronary atherosclerosis, rheumatoid arthritis, tumor invasion, metastasis, angiogenesis, multiple sclerosis, periodontal disease, restenosis, heart failure, osteoporosis, liver cirrhosis |
| 05/25/2006 | US20060111322 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |